|
CLINICAL TRIALS |
| The ongoing FDA-supervised Phase II clinical trials for antineoplastons include 35 protocols for cancer patients of both sexes, all ages and various forms of cancer. Treatment for patients who qualify for enrollment is administered by the Burzynski Clinic, which provides free information for prospective participants. (www.cancermed.com) |
|
|
OPEN PROTOCOLS
Below table lists current open protocols. For description and criteria of each protocol, click on the blue link in the right side of the table.
|
Protocol ID |
Title |
Description and Criteria | |
| AD-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH CARCINOMA OF THE ADRENAL GLAND | Description AD-02 | |
| BL-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH CARCINOMA OF THE BLADDER | Description BL-02 | |
| BR-10 | STUDY OF ANTINEOPLASTONS A10 IN COMBINATION WITH LOW DOSE METHOTREXATE IN PATIENTS WITH ADVANCED BREAST CANCER | Description BR-10 | |
| BR-14 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 CAPSULES IN PATIENTS WITH ADVANCED BREAST CANCER | Description BR-14 | |
| BT-06 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH HIGH GRADE GLIOMA | Description BT-06 | |
| BT-08 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA | Description BT-08 | |
| BT-09 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH BRAIN TUMORS | Description BT-09 | |
| BT-10 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH BRAIN TUMOR | Description BT-10 | |
| BT-11 | PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN PATIENTS WITH BRAIN STEM GLIOMA | Description BT-11 | |
| BT-12 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS | Description BT-12 | |
| BT-13 | PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1IN CHILDREN WITH LOW GRADE ASTROCYTOMA | Description BT-13 | |
| BT-14 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1IN CHILDREN WITH RHABDOID TUMOR OF THE CENTRAL NERVOUS SYSTEM | Description BT-14 | |
| BT-15 | PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA | Description BT-15 | |
| BT-17 | PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN ADULT PATIENTS WITH OLIGODENDROGLIOMA | Description BT-17 | |
| BT-18 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN ADULT PATIENTS WITH MIXED GLIOMA | Description BT-18 | |
| BT-21 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN ADULT PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS | Description BT-21 | |
| BT-22 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1IN CHILDREN WITH PRIMARY MALIGNANT BRAIN TUMORS | Description BT-22 | |
| BT-23 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN CHILDREN WITH VISUAL PATHWAY GLIOMA | Description BT-23 | |
| BT-24 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN PATIENTS WITH EPENDYMOMA | Description BT-24 | |
| BT-34 | PHASE II STUDY OF MAINTENANCE TREATMENT WITH ANTINEOPLASTONS A10 AND AS2-1 CAPSULES FOR PATIENTS WITH MALIGNANCIES IN COMPLETE RESPONSE FOLLOWING INITIAL INTRAVENOUS TREATMENT WITH ANTINEOPLASTONS A10 AND AS2-1 | Description BT-34 | |
| BT-35 | PHASE II STUDY OF TREATMENT WITH ANTINEOPLASTONS A10 AND AS2-1 CAPSULES FOR PATIENTS WITH MALIGNANCIES IN PARTIAL RESPONSE OR STABLE DISEASE FOLLOWING INITIAL INTRAVENOUS TREATMENT WITH ANTINEOPLASTONS A10 AND AS2-1 | Description BT-35 | |
| CO-03 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 CAPSULES IN PATIENTS WITH ADENOCARCINOMA OF THE COLON | Description CO-03 | |
| ES-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH ADENOCARCINOMA OF THE ESOPHAGUS | Description ES-02 | |
| LA-04 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH LARGE CELL, UNDIFFERENTIATED OR POORLY DIFFERENTIATED CARCINOMA OF THE LUNG | Description LA-04 | |
| LY-03 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA | Description LY-03 | |
| LY-06 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, LOW GRADE | Description LY-06 | |
| LY-09 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH MANTLE ZONE LYMPHOMA | Description LY-09 | |
| LY-12 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA | Description LY-12 | |
| MA-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH MESOTHELIOMA | Description MA-02 | |
| ME-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH MALIGNANT MELANOMA | Description ME-02 | |
| MM-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH MULTIPLE MYELOMA | Description MM-02 | |
| NE-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH NEUROENDOCRINE TUMORS | Description NE-02 | |
| PA-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH CARCINOMA OF THE PANCREAS | Description PA-02 | |
| PR-06 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 CAPSULES IN COMBINATION WITH TOTAL ANDROGEN BLOCKADE IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE | Description PR-06 | |
| UP-02 | PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH ADENOCARCINOMA OF AN UNKOWN PRIMARY | Description UP-02 |